Safety Evaluation of Human Living Skin Equivalents

Abstract

Human living skin equivalents (LSEs) offer an alternative to the use of split-thickness autografts for the treatment of hard-to-heal wounds. LSEs consist of 4 active components: a well-differentiated stratum corneum derived from epidermal keratinocytes, dermal fibroblasts, and an extracellular collagen matrix. Neonatal foreskins are used as the source of keratinocytes and dermal fibroblasts for the manufacture of LSEs. Following isolation and expansion in vitro, the cells are cultured on a 3-dimensional scaffold to give an upper epidermal layer and supporting dermal layer. The resulting product has the appearance and handling characteristics of human skin. Safety evaluation of LSEs begins with insuring that foreskins are obtained only from healthy infants whose mothers are negative for a panel of adventitious agents. Keratinocyte and fibroblast cell banks are characterized using morphologic, biochemical, and histologic criteria; checked for the absence of contaminating cell types such as melanocytes, macrophages, lymphocytes, and Langerhans cells; subjected to rigorous microbiological testing (with any production materials of biological origin); and evaluated for in vivo tumorigenicity. The consistency of certain key morphologic and functional characteristics are regularly assessed. Because an LSE represents an allogeneic graft, preclinical safety studies include in vitro and in vivo determinations of its potential immunogenicity. Immunocompromised (SCID) mice reconstituted with human leukocytes or engrafted with human fetal hematolymphoid organs have been useful animal models for assessing possible immunologic responses to LSEs. Additional preclinical studies are being conducted to show that LSEs are noncytotoxic and lack allergenic, sensitizing, or irritation potential.

Keywords

Allograft keratinocyte fibroblast skin substitute collagen Apligraf™tissue engineering skin equivalent

References

Bell E. and Rosenberg M. (1990). The commercial use of cultivated human cells. Transplant. Proc. 22: 971-974.

Bennett NT and Schultz GS (1993). Growth factors and wound healing: Biochemical properties of growth factors and their receptors. Am. J. Surg. 165: 728-737.

Braunstein S. , Kaplan G. , Gottlieb AB , Schwartz M. , Walsh G. , Abalos RM , Fajardo TT , Guido LS , and Krueger JG (1994). GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo. J. Invest. Dermatol. 103: 601-604.

Eaglstein WH , Iriondo M. , and Laszlo K. (1995). A composite skin substitute (Graftskin) for surgical wounds. Dermatol. Surg. 21: 839-843.

Falanga V. (1993). Venous ulceration. J. Dermatol. Surg. Oncol. 19: 764-771.

Falanga V. , Margolis D. , Alvarez O. , Auletta M. , Maggiacomo F. , Altman M. , Jensen J. , Sabolinski M. , Hardin-Young J. (1998). Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch. Dermatol. 134: 293-300.

Ganio C. , Tenewitz FE , Wilson RC , and Moyles BG (1993). The treatment of chronic nonhealing wounds using autologous platelet-derived growth factors. J. Foot Ankle Surg. 32: 263-268.

Hansbrough JF , Morgan J. , Greenleaf G. , Parikh M. , Nolte C. , and Wilkins L. (1994). Evaluation of Graftskin composite grafts on full-thickness wounds on athymic mice. J. Burn Care Rehabil. 15: 346-353.

Hardin-Young J. , Isaacs C. , Prosky S. , Nolte C. , Pliss N. , and Parenteau N. (1995). Human Immune Response to Bilayered Cultured Allogeneic Skin Grafts. Keystone Symposia, March 1994, in Taos, New Mexico.

10.

Margolis DJ and Cohen JH (1994). Management of chronic venous leg ulcers: A literature-guided approach. Clin. Dermatol. 12: 19-26.

11.

Nickoloff BJ and Turka LA (1994). Immunological functions of non-professional antigen-presenting cells: New insights from studies of T-cell interactions with keratinocytes. Immunol. Today 15: 464-469.

12.

Nolte Cjm , Oleson MA , Hansbrough JF , Morgan J. , Greenleaf G. , and Wilkins L. (1994). Ultrastructural features of composite skin cultures grafted onto athymic mice. J. Anat. 185: 325-333.

13.

Nolte Cjm , Oleson MA , Bilbo PR , and Parenteau NL (1993). Development of a stratum corneum and barrier function in an organotypic skin culture. Arch. Dermatol. Res. 285: 466-474.

14.

Parenteau NL (1994). Skin equivalents. In: The Keratinocyte Handbook, I Leigh and F Watts (eds). Cambridge University Press , London, pp. 44-54.

15.

Parenteau NL , Bilbo P. , Nolte Cjm , Mason VS , and Rosenberg M. (1992). The organotypic culture of human skin keratinocytes and fibroblasts to achieve form and function. Cytotechnology 9: 163-171.

16.

Phillips LG , Abdullah KM , Geldner PD , Dobbins S. , Ko F. , Linares HA , Broemeling LD , and Robson MC (1993). Application of basic fibroblast growth factor may reverse diabetic wound healing impairment. Ann. Plast. Surg. 31: 331-334.

17.

Phillips TJ (1998). New skin for old. Arch. Dermatol. 134: 344-349.

18.

Phillips T. , Stanton B. , Provan A. , and Lew R. (1994). A study of the impact of leg ulcers on quality of life: Financial, social, and psychological implications . J. Am. Acad. Dermatol. 31: 49-53.

19.

Phipps R. , Roper RL , and Stein SH (1989). Alternative antigen presentation pathways: Accessory cells which down-regulate immune responses. Regul. Immunol . 2: 326-339.

20.

Theobald VA , Lauer JD , Kaplan FA , Baker KB , and Rosenberg M. (1993). Neutral allografts—Lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens. Transplantation 55: 128-133.

21.

Waldorf H. and Fewkes J. (1995). Wound healing. Adv. Dermatol. 10: 77-96.

22.

Wilkins LM , Watson SR , Prosky SJ , Meunier SF , and Parenteau NL (1994). Development of a bilayered living skin construct for clinical applications. Biotechnol. Bioeng. 43: 747-756.